Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Saegis Pharmaceuticals |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00093951 |
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
Condition | Intervention | Phase |
---|---|---|
Alzheimer's Disease |
Drug: SGS742 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease |
Estimated Enrollment: | 280 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | December 2004 |
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Ages Eligible for Study: | 55 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Prohibited Meds:
Study ID Numbers: | IA0061 |
Study First Received: | October 7, 2004 |
Last Updated: | February 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00093951 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Alzheimer disease memory cognition GABA(B)receptor antagonist |
Neurotransmitter Agents Delirium, Dementia, Amnestic, Cognitive Disorders (3-aminopropyl)(n-butyl)phosphinic acid Mental Disorders Alzheimer Disease Central Nervous System Diseases |
Neurodegenerative Diseases Brain Diseases Dementia Neuroprotective Agents Cognition Disorders Delirium |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action (3-aminopropyl)(n-butyl)phosphinic acid Alzheimer Disease Nervous System Diseases Physiological Effects of Drugs Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Neuroprotective Agents |
Protective Agents Pharmacologic Actions GABA Antagonists Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Therapeutic Uses GABA Agents Dementia Tauopathies Central Nervous System Agents |